Miller K - Search Results

1

Management of Metastatic Bone Disease Algorithms for Diagnostics and Treatment.

Jehn CF, Diel IJ, Overkamp F, Kurth A, Schaefer R, Miller K, Lüftner D. Jehn CF, et al. Among authors: miller k. Anticancer Res. 2016 Jun;36(6):2631-7. Anticancer Res. 2016. PMID: 27272771 Review.

2

Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.

Johannsen M, Flörcken A, Bex A, Roigas J, Cosentino M, Ficarra V, Kloeters C, Rief M, Rogalla P, Miller K, Grünwald V. Johannsen M, et al. Among authors: miller k. Eur Urol. 2009 Jun;55(6):1430-8. doi: 10.1016/j.eururo.2008.10.021. Epub 2008 Oct 18. Eur Urol. 2009. PMID: 18950936

3

Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid.

Lein M, Miller K, Wirth M, Weissbach L, May C, Schmidt K, Haus U, Schrader M, Jung K. Lein M, et al. Among authors: miller k. Prostate. 2009 May 1;69(6):624-32. doi: 10.1002/pros.20917. Prostate. 2009. PMID: 19143027 Clinical Trial.

4

New markers and multivariate models for prostate cancer detection.

Stephan C, Rittenhouse H, Cammann H, Lein M, Schrader M, Deger S, Miller K, Jung K. Stephan C, et al. Among authors: miller k. Anticancer Res. 2009 Jul;29(7):2589-600. Anticancer Res. 2009. PMID: 19596933 Free article. Review.

5

Bone turnover markers as predictors of mortality risk in prostate cancer patients with bone metastases following treatment with zoledronic acid.

Jung K, Miller K, Wirth M, Albrecht M, Lein M. Jung K, et al. Among authors: miller k. Eur Urol. 2011 Apr;59(4):604-12. doi: 10.1016/j.eururo.2010.12.006. Epub 2010 Dec 22. Eur Urol. 2011. PMID: 21190792

6

Selective lymph node dissection for castration-resistant prostate cancer.

Busch J, Hinz S, Kempkensteffen C, Erber B, Klopf C, Weikert S, Miller K, Magheli A. Busch J, et al. Among authors: miller k. Urol Int. 2012;88(4):441-6. doi: 10.1159/000335206. Epub 2012 Mar 7. Urol Int. 2012. PMID: 22398510

7

Harnessing the potential of therapeutic agents to safeguard bone health in prostate cancer.

Miller K, Steger GG, Niepel D, Lüftner D. Miller K, et al. Prostate Cancer Prostatic Dis. 2018 Nov;21(4):461-472. doi: 10.1038/s41391-018-0060-y. Epub 2018 Jul 9. Prostate Cancer Prostatic Dis. 2018. PMID: 29988100 Free PMC article.

8

Neoadjuvant and adjuvant end-points in health technology assessment in oncology.

Harbeck N, Schneeweiss A, Thuss-Patience P, Miller K, Garbe C, Griesinger F, Eberhardt WEE, Klussmann JP, Wollenberg B, Grimm MO, Zander T, Lüftner D. Harbeck N, et al. Among authors: miller k. Eur J Cancer. 2021 Apr;147:40-50. doi: 10.1016/j.ejca.2021.01.006. Epub 2021 Feb 19. Eur J Cancer. 2021. PMID: 33611103 Review.

9

Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic Acid for detection of bone metastases progression.

Lein M, Wirth M, Miller K, Eickenberg HU, Weissbach L, Schmidt K, Haus U, Stephan C, Meissner S, Loening SA, Jung K. Lein M, et al. Among authors: miller k. Eur Urol. 2007 Nov;52(5):1381-7. doi: 10.1016/j.eururo.2007.02.033. Epub 2007 Feb 20. Eur Urol. 2007. PMID: 17321667 Clinical Trial.

10

Plasma matrix metalloproteinase-7 as a metastatic marker and survival predictor in patients with renal cell carcinomas.

Ramankulov A, Lein M, Johannsen M, Schrader M, Miller K, Jung K. Ramankulov A, et al. Among authors: miller k. Cancer Sci. 2008 Jun;99(6):1188-94. doi: 10.1111/j.1349-7006.2008.00802.x. Epub 2008 Apr 14. Cancer Sci. 2008. PMID: 18422740 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

7,537 results

Search Page